1542268-31-4

Usage

Uses

Used in Pharmaceutical Industry:
(3R,5R)-3,5-Dimethyl-morpholine hydrochloride is used as a key intermediate in the synthesis of KIF18A inhibitors for the treatment of cancer. KIF18A is a motor protein involved in cell division, and its inhibition can potentially lead to the prevention of cancer cell proliferation and the development of new therapeutic strategies against cancer.

Upstream product

• 2749-11-3 (S)-Alaninol 
• 116-09-6 hydroxy-2-propanone 
• 942309-59-3 meso-3,5-dimethylmorpholine-4-carboxylic acid tert-butyl ester 
• 256518-81-7 C₆H₁₃NO*ClH 
• 2294-46-4 bis(2-hydroxy-1-methylethyl)amine 
• 7664-93-9 sulfuric acid 
• 154634-95-4 (3S,5S)-4-tert-butoxycarbonyl-3,5-dimethylmorpholine 
• 218595-23-4 C₆H₁₃NO*ClH 
• 942309-58-2 2-[(S)-2-hydroxy-1-methylethylamino]propan-1-ol 
• 154596-18-6 (3S,5R)-4-tert-butoxycarbonyl-3,5-dimethylmorpholine 

Relevant academic research and scientific papers

(S,S)-3,5-dimethylmorpholine, a novel C2-symmetric auxiliary. First application in [4 + 2]-cycloadditions leading to 4-oxohexahydropyridazine derivatives

Diastereoselective Diels-Alder reactions of (S,S)-2-(3,5-dimethylmorpholino)butadienes 10 with aza-dienophiles are described, leading to cycloadducts 12 in good yields and high stereoselectivities (de = 87-96%). After double bond migration to 13, acidic a

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical ac-ceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway

TRIAZOLYL DERIVATIVES AS SYK INHIBITORS

Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

VLA-4 INHIBITORY DRUG

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I): wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, orabenzyloxygroupwhichmaybe substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group whichmaybe substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C-R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group), or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.

AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS

This invention relates to piperazine derivatives of formula (I), wherein Y is bond or lower alkylene, R1 is aryl which may have substituent(s), R2 is aryl or indolyl, each of which may have substituent(s), R3 is hydrogen or lower alkyl, and R4 is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human beings or animals. 1

FKBP inhibitors

Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.